PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway.

about

Nutritional approaches for managing obesity-associated metabolic diseases.Role of low-grade inflammation in osteoarthritis.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.

P2860

Q30234850-BFC32018-D94D-4770-A6DB-E148F23D47DE Q38984248-8DCBC04F-7F51-4E68-9A48-3B866666D090 Q39200940-FE9B93A2-2806-43E2-A149-3BB745F611AD

P2860

PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway.

Item

http://www.wikidata.org/entity/Q51684349

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

PPAR-α Agonist WY-14643 Inhibi ...... Fibroblasts via NF-kB Pathway.

@en

PPAR-α Agonist WY-14643 Inhibi ...... Fibroblasts via NF-kB Pathway.

@nl

type

Item

label

PPAR-α Agonist WY-14643 Inhibi ...... Fibroblasts via NF-kB Pathway.

@en

PPAR-α Agonist WY-14643 Inhibi ...... Fibroblasts via NF-kB Pathway.

@nl

prefLabel

PPAR-α Agonist WY-14643 Inhibi ...... Fibroblasts via NF-kB Pathway.

@en

PPAR-α Agonist WY-14643 Inhibi ...... Fibroblasts via NF-kB Pathway.

@nl

P1476

PPAR-α Agonist WY-14643 Inhibi ...... Fibroblasts via NF-kB Pathway.

@en

P2093

Degang Huang

http://www.w3.org/2001/XMLSchema#string

Hongfei Liu

http://www.w3.org/2001/XMLSchema#string

Hongguang Xu

http://www.w3.org/2001/XMLSchema#string

Quanlai Zhao

http://www.w3.org/2001/XMLSchema#string

Yongjie Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha

Proinflammatory signaling regulates hematopoietic stem cell emergence.

Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula

American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee.

Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-κB translocation and MAPK/ERK phosphorylation.

Poxvirus Protein MC132 from Molluscum Contagiosum Virus Inhibits NF-B Activation by Targeting p65 for Degradation.

Emerging targets in osteoarthritis therapy.

Low-grade inflammation in symptomatic knee osteoarthritis: prognostic value of inflammatory plasma lipids and peripheral blood leukocyte biomarkers

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence.

Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.

P2888

s12031-016-0775-y

P304

544-553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12031-016-0775-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27339772

http://www.w3.org/2001/XMLSchema#string

PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway.

about

P2860

P2860

PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698